Q1 2020 EPS Estimates for Cooper Companies Inc (NYSE:COO) Decreased by Analyst

Cooper Companies Inc (NYSE:COO) – Piper Jaffray Companies decreased their Q1 2020 earnings per share estimates for Cooper Companies in a report released on Thursday, December 5th. Piper Jaffray Companies analyst M. O’brien now expects that the medical device company will post earnings of $2.70 per share for the quarter, down from their prior estimate of $3.03. Piper Jaffray Companies has a “Buy” rating and a $344.00 price objective on the stock. Piper Jaffray Companies also issued estimates for Cooper Companies’ Q2 2020 earnings at $3.11 EPS, FY2020 earnings at $12.76 EPS, Q1 2021 earnings at $2.98 EPS, Q2 2021 earnings at $3.43 EPS, Q3 2021 earnings at $3.75 EPS, Q4 2021 earnings at $3.91 EPS, FY2021 earnings at $14.07 EPS and FY2022 earnings at $15.58 EPS.

Cooper Companies (NYSE:COO) last posted its quarterly earnings data on Thursday, December 5th. The medical device company reported $3.30 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.27 by $0.03. The business had revenue of $691.60 million during the quarter, compared to the consensus estimate of $683.83 million. Cooper Companies had a net margin of 17.59% and a return on equity of 17.38%. Cooper Companies’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.87 EPS.

Other analysts also recently issued reports about the stock. Jefferies Financial Group decreased their price objective on shares of Cooper Companies from $358.00 to $330.00 and set an “in-line” rating for the company in a report on Wednesday, December 4th. Northcoast Research reaffirmed a “buy” rating on shares of Cooper Companies in a report on Tuesday, December 3rd. Zacks Investment Research raised shares of Cooper Companies from a “sell” rating to a “hold” rating and set a $325.00 price objective for the company in a report on Wednesday, November 20th. Raymond James cut their target price on shares of Cooper Companies from $364.00 to $355.00 and set an “in-line” rating for the company in a research note on Friday, December 6th. Finally, KeyCorp upped their target price on shares of Cooper Companies from $348.00 to $351.00 and gave the company an “overweight” rating in a research note on Wednesday, November 27th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $328.73.

NYSE COO opened at $304.54 on Monday. The company has a current ratio of 1.05, a quick ratio of 0.59 and a debt-to-equity ratio of 0.35. The company has a fifty day simple moving average of $299.54 and a 200 day simple moving average of $312.31. The company has a market cap of $14.98 billion, a P/E ratio of 24.66, a P/E/G ratio of 2.23 and a beta of 0.91. Cooper Companies has a 1 year low of $228.65 and a 1 year high of $344.32.

A number of large investors have recently added to or reduced their stakes in COO. Signaturefd LLC raised its stake in shares of Cooper Companies by 3.8% in the 2nd quarter. Signaturefd LLC now owns 875 shares of the medical device company’s stock valued at $295,000 after buying an additional 32 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Cooper Companies by 0.4% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,282 shares of the medical device company’s stock valued at $3,464,000 after buying an additional 38 shares in the last quarter. Advisory Services Network LLC raised its stake in shares of Cooper Companies by 13.6% in the 2nd quarter. Advisory Services Network LLC now owns 318 shares of the medical device company’s stock valued at $107,000 after buying an additional 38 shares in the last quarter. United Capital Financial Advisers LLC raised its stake in shares of Cooper Companies by 2.8% in the 2nd quarter. United Capital Financial Advisers LLC now owns 1,435 shares of the medical device company’s stock valued at $483,000 after buying an additional 39 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. raised its stake in shares of Cooper Companies by 0.5% in the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 8,894 shares of the medical device company’s stock valued at $2,996,000 after buying an additional 41 shares in the last quarter. Hedge funds and other institutional investors own 95.35% of the company’s stock.

Cooper Companies Company Profile

The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.

Further Reading: Understanding Market Liquidity

Earnings History and Estimates for Cooper Companies (NYSE:COO)

Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.